We knew from previously released documents that Reuters reporter Kate Kelland was a key connection for Monsanto in its endeavor to undermine and discredit the World Health Organization’s International Agency for Research on Cancer (IARC) scientists who classified glyphosate as a probable carcinogen in 2015. Now we have additional evidence of the coziness of the connection.
Not only did Kelland write a 2017 story that Monsanto asked her to write in exactly the way Monsanto executive Sam Murphey asked her to write it, (without disclosing to readers that Monsanto was the source,) but now we see evidence that a draft of a separate story Kelland did about glyphosate was delivered to Monsanto before it was published, a practice typically frowned on by news outlets.
The emails shows the story written by Kelland was emailed to Murphey with the subject line “My draft, Confidential.”
The story, headlined “New study on Monsanto weed killer to feed into crucial EU vote,” was about preliminary findings of an unpublished study by an Italian scientist showing that experimental rats exposed to glyphosate at levels equivalent to those allowed in humans showed no initial adverse reaction. The final version was published on April 13, 2017.
And another newly released email details how Monsanto’s fingerprints were on at least two other Kelland stories. The March 1, 2016 email speaks of the involvement of Monsanto’s “Red Flag” campaign in an already published Reuters story that was critical of IARC and the desire to influence a second similar story Reuters was planning. Red Flag is a Dublin-based PR and lobbying firm that works to defend glyphosate safety and promote pro-glyphosate messaging via third parties such as farmer groups.
According to the partly redacted email, “following engagement by Red Flag a number of months ago, the first piece was quite critical of IARC.” The email goes on: “You may also be aware that Red Flag is in touch with Reuters regarding the second report in the series…”
Those revelations follow the disclosure earlier this year of email correspondence detailing how Kelland helped Monsanto drive a false narrative about cancer scientist Aaron Blair in his role as head of the IARC working group that classified glyphosate as a probable carcinogen. Internal Monsanto correspondence dated April 27, 2017 shows that Monsanto executive Sam Murphey sent the company’s desired narrative to Kelland with a slide deck of talking points and portions of the Blair deposition that was not filed in court.
On June 14, 2017, Kelland authored a controversial story based on what she said were “court documents,” that in reality were documents fed to her by Murphey. Because the documents Kelland cited were not really filed in court they were not publicly available for easy fact-checking by readers. By falsely attributing the information as based on court documents she avoided disclosing Monsanto’s role in driving the story.
When the story came out, it portrayed Blair as hiding “important information”that found no links between glyphosate and cancer from IARC. Kelland wrote that a deposition showed that Blair “said the data would have altered IARC’s analysis” even though a review of the actual deposition shows that Blair did not say that.
Kelland provided no link to the documents she cited, making it impossible for readers to see for themselves how far she veered from accuracy.
The story was picked up by media outlets around the world, and promoted by Monsanto and chemical industry allies. Google advertisements were even purchased promoting the story. This story was also used by Monsanto to attack IARC on multiple fronts, including an effort by Monsanto to get Congress to strip funding from IARC.
There is nothing inherently wrong in receiving story suggestions that benefit companies from the companies themselves. It happens all the time. But reporters must be diligent in presenting facts, not corporate propaganda.
Reuters editor Mike Williams has defended Kelland’s work and declined to issue a clarification or correction on the Aaron Blair piece. He said “It was a great piece, and I stand by it fully.” Reuters “ethics editor” Alix Freedman also supports Kelland’s Blair story, despite the evidence of Monsanto’s involvement and the lack of disclosure of that involvement to readers. “We are proud of it and stand behind it,” Freedman said in an email. On a personal note, I spent 17 years as a reporter at Reuters covering Monsanto and I am horrified at this violation of journalistic standards. It is particularly noteworthy that Alix Freedman is the same person who told me I was not allowed to write about many independent scientific studies of Monsanto’s glyphosate that were showing harmful impacts .
At the very least, Kelland should have been honest with readers and acknowledged that Monsanto was her source – on that story, and apparently many others. Reuters owes the world – and IARC – an apology.
Records Show EPA Efforts To Slow Herbicide Review Came In Coordination With Monsanto
Newly released government email communications show a persistent effort by multiple officials within the Environmental Protection Agency (EPA) to slow a separate federal agency’s safety review of Monsanto’s top-selling herbicide. Notably, the records demonstrate that the EPA efforts came at the behest of Monsanto, and that EPA officials were helpful enough to keep the chemical giant updated on their progress.
The communications, most of which were obtained through Freedom of Information Act (FOIA) requests, show that it was early 2015 when the EPA and Monsanto began working in concert to stall a toxicology review that a unit tied to the Centers for Disease Control and Prevention (CDC) was conducting on glyphosate, the key ingredient in Monsanto’s branded Roundup herbicide products. The details revealed in the documents come as Monsanto is defending itself against lawsuits alleging that it has tried to cover up evidence of harm with its herbicides.
The Agency for Toxic Substances and Disease Registry (ATSDR), a federal public health agency that along with the CDC is part of the U.S. Department of Health and Human Services (HHS), is charged with evaluating the potential adverse human health effects from exposures to hazardous substances in the environment. So it made sense for the ATSDR to take a look at glyphosate, which is widely used on U.S. farms, residential lawns and gardens, school playgrounds and golf courses. Glyphosate is widely used in food production and glyphosate residues have been found in testing of human urine.
The ATSDR announced in February 2015 that it planned to publish a toxicological profile of glyphosate by October of that year. But by October, that review was on hold, and to this date no such review has yet been published. (Update: the draft review was finally published in April 2019.) The documents reveal this was no accident, no bureaucratic delay, but rather was the result of a collaborative effort between Monsanto and a group of high-ranking EPA officials.
For Monsanto, the timing of the ATSDR review was worrisome. In March 2015, the World Health Organization’s International Agency for Research on Cancer (IARC) had declared glyphosate to be a probable human carcinogen, and Monsanto feared ATSDR might have similar concerns about the chemical. Previous reports have described how one EPA official, Jess Rowland, communicated to Monsanto in April 2015 his willingness to try to kill the ATSDR review. Rowland, who retired in 2016, was the deputy division director within the health effects division of the EPA’s Office of Pesticide Programs (OPP). Allegations of collusion between Rowland and Monsanto have prompted a probe by the EPA’s Office of Inspector General.
But the trove of documents newly obtained from within EPA and HHS demonstrate that the assistance to Monsanto came not only from Rowland but also from even higher-level EPA officials. Rather than encourage and assist the toxicology review of glyphosate, Monsanto and EPA officials repeatedly complained to ATSDR and HHS that such a review was unnecessarily “duplicative” and should take a back seat to an EPA review also underway.
The following timeline shows how the events unfolded:
May 19, 2015 – Michael Dykes, who at that time was Monsanto’s long-time vice president of government affairs, wrote directly to the EPA’s Jim Jones, the Assistant Administrator for the Office of Chemical Safety & Pollution Prevention. Jones had oversight of the EPA’s Office of Pesticide Programs (OPP) and was a presidential appointee who carried significant clout. The afternoon was waning when the email came in at 3:28 p.m. Dykes reminded Jones that they had recently discussed the HHS’ ATSDR glyphosate review at a meeting.
“You were not aware of their review. Did you learn anything more about their efforts?” Dykes asked.
Jones did not waste time. Roughly an hour later he forwarded the message to OPP Director Jack Housenger, writing “Monsanto thinks atsdr is doing a glyphosate Assessment. Could you guys run that down?” Housenger responds quickly: “Yes. Jess checked with them…. It has been difficult to get information.”
Within an hour Jones instructed a member of his staff to get him contact information for the head person responsible for ATSDR. She replied the next morning that Dr. Patrick Breysse was the point person. Breysse joined the CDC in 2014 as director of its National Center for Environmental Health, overseeing the NCEH’s ATSDR.
May 20, 2015 It was only a little after 8:30 a.m. but Jones told the staff member to instruct Housenger to get in touch with Breysse, and within two hours Housenger had penned an email to Breysse explaining that an EPA’s own re-evaluation/risk assessment of glyphosate was nearing completion, and asking Breysse if “you would still feel the need to do your assessment.” Housenger told Breysse that he already had reached the individual assigned to the ATSDR assessment and she had indicated she would “coordinate” with EPA, but that was not sufficient. Housenger did not mention Monsanto’s outreach to EPA on the issue, but instead questioned “whether this is a good use of government resources” for ATSDR to continue with its review. Breysse responded that he would “look into this” and Housenger thanked him for his quick response. Breysse then reached out to an ATSDR division director named James Stephens to arrange a discussion about the EPA request.
May 21, 2015 James Stephens wrote back to Patrick Breysse that the ATSDR team thought the EPA work “overlaps but isn’t totally duplicative…” and stated that the ASTDR team has not been able to see draft copies of the EPA’s work. “I think we would all welcome further discussion with EPA but would hope to use it to help us find out more about what they are doing, ” he told Breysse. After hearing from Stephens, Breysse wrote back to Housenger saying ATSDR staff would be in touch to discuss. Housenger replied with his reiteration that the ATSDR review would be a “duplicative government effort” and that the EPA draft would be out in July of 2015. (As of this writing, that EPA preliminary risk assessment still has not been released, though in 2016 the EPA did release a cancer assessment report that declared glyphosate was not likely to cause cancer.)
June 4, 2015 Pressing the issue, EPA’s Housenger wrote again to Breysee to say he had not heard from anyone yet. The ATSDR’s Stephens wrote back promising to make sure “someone gives you a ring.”Internal Monsanto emails show that at the same time, Monsanto was also pushing the “duplicative” narrative with HHS, meeting on June 4 with HHS Deputy Assistant Secretary for Global Health Mitchel Wolfe to ask him to help repudiate the IARC classification and to recognize that a review of glyphosate was “not the primary role” for his agency. “Dr. Wolfe said he would follow up on what was going on with ATSDR and he was encouraged to have discussions with EPA staff, as well,” a Monsanto memo detailing the meeting states.
June 9, 2015 Henry Abadin, an ATSDR supervisory scientist, reported to Stephens that he had talked with Housenger and explained that the agency did not believe it was “duplicating efforts.” Nevertheless, he said he told EPA, “we did not have a problem with putting the glyphosate profile on hold, pending the OPP final report.”
June 19, 2015 To further ensure the ATSDR review didn’t move forward, Monsanto’s Dykes talked again with HHS’s Wolfe, asking for an update on ATSDR. “I explained… our question was about the purpose and scope of such a duplicative review by ATSDR. I also told him that we were concerned that ATSDR may come out any day with a report. I again stressed that we were concerned that they were even reviewing glyphosate as were the people we talked with at EPA,” Dykes wrote to colleagues.
June 21, 2015 It was a Sunday, but Monsanto’s Dykes was still concerned enough about the ATSDR review to copy multiple colleagues on a late night email to report that he had continued to press the “duplicative” point with ATSDR but was concerned about a “glyphosate review coming any day.”In a text message sent that same day, Monsanto scientist Eric Sachs reached out to a former EPA toxicologist named Mary Manibusan asking for contacts at ATSDR. “We’re trying to do everything we can to keep from having a domestic IARC occur w this group. may need your help,” Sachs wrote. The text messages were among certain internal Monsanto records obtained by cancer victims who are suing Monsanto alleging Roundup caused their diseases.
June 23, 2015 By Tuesday, Monsanto’s Jenkins had good news: He had heard from Housenger that the EPA official had been successful in garnering a promise from ATSDR to put its report “on hold.” The review was not dead, however, he wrote: ATSDR argues “that their process is distinguishable and not duplicative. They look at different endpoints and told EPA they don’t “make a call on cancer”, but I think we should continue to be cautious.”
On June 24,2015 Monsanto’s chief scientist William Heydens responded: “’Distinguishable and not duplicative’? Seriously? And I will believe the not ‘making a call on cancer’ part when I see it. Anyway, at least they know they are being watched, and hopefully that keeps them from doing anything too stupid…” Jenkins wrote back, acknowledging that Monsanto had much more to fear from ATSDR than EPA as the two agencies had arrived at “different conclusions” on other issues. He reported he had been told ATSDR was “VERY conservative and IARC like…”
By October 23, 2015 EPA and Monsanto had the ATSDR review fully on hold. EPA’s Housenger wrote to update Monsanto’s Jenkins: “They are waiting for our glyphosate RA. And they agreed to share what they do.”
That same month, the EPA’s Cancer Assessment Review Committee (CARC), which was chaired by Rowland, issued an internal report stating that contrary to IARC, the EPA’s review of glyphosate found it “not likely to be carcinogenic to humans.”
The EPA still has yet to issue the overall new risk assessment it said would be out in 2015. The agency has offered ever-changing timelines for the assessment, but now says its intends to release a draft risk assessment sometime this year. That will be followed by a 60-day public comment period. After the public comment period the EPA will determine whether any risk management is needed. In the meantime, Monsanto has cited the EPA’s backing of glyphosate safety as repudiation of the IARC finding both in court and with regulators in Europe who are also looking at glyphosate safety issues.
The EPA did not respond to a request for comment about its efforts to delay the ATSDR report or communications with Monsanto regarding that effort.
But Brent Wisner, a lawyer representing many of the cancer victims who are suing Monsanto, said the documents offer damning evidence of improperly close ties between the EPA and the chemical company. “I think it’s very clear… that EPA officials and Monsanto employees worked together to accomplish a goal of stopping that analysis at ATSDR. That is collusion. I don’t know what else you’d call that,” said Wisner.
For its part, the ATSDR said this week that the review it started in 2015 “is not complete” but that it anticipates a draft glyphosate toxicological profile to be issued for public comment by the end of this year. A spokesperson for the agency declined to discuss the circumstances surrounding the delay in the review.
And Jones, whose EPA job ended when the Trump administration took over, defended his responsiveness to Monsanto’s concern about the ATSDR review, saying it had only to do with the “efficient use of government resources.”
“Had any party contacted me and informed me that another agency within the Administration was simultaneously assessing a chemical as my organization, I would have intervened,” Jones said. “There is no value to the same government investing limited resources to work on the same issue. As you know resources at the federal level were and are scarce which made duplication even more problematic.” Jones said additionally that “when two organizations assess the same chemical, it is very likely there will be differences in their assessments.Even when these differences don’t matter from a public health perspective, an enormous amount of energy is spent attempting to resolve these differences” and that is not ultimately in the “public interest.”
Bayer Makes Bid for “Trust” Amid Third Monsanto Cancer Trial
Bayer AG, which bought Monsanto last summer, said Monday that it was making scientific studies available for public scrutiny in an effort to counter growing concerns about the safety of Monsanto’s flagship glyphosate-based herbicide products.
“Transparency is a catalyst for trust, so more transparency is a good thing for consumers, policymakers and businesses, Liam Condon, president of Bayer’s crop science division, said in a statement. Safety, he said, is the company’s top priority.
The comments come as pressure is mounting on Bayer management as roughly 11,000 people are suing Monsanto alleging glyphosate-based herbicides such as Roundup cause non-Hodgkin lymphoma, and Monsanto has hidden the risks and manipulated the scientific record. The first Roundup cancer trial resulted in a jury verdict of $289 million in damages against Monsanto, though a judge later lowered that to $78 million. The second such trial ended last month with a jury verdict of $80.2 million against Monsanto. The third trial is now underway.
Last week U.S. District Judge Vince Chhabria told Bayer attorneys and plaintiffs’ attorneys that he would like the parties to enter into mediation to discuss a possible settlement. He vacated a fourth trial set to begin in May.
Monsanto and Bayer deny the allegations and say the weight of science supports the safety of glyphosate herbicides. They also deny claims that company scientists ghost-wrote seemingly independent scientific papers and otherwise manipulated the scientific record.
“By making our detailed scientific safety data available, we encourage anyone interested to see for themselves how comprehensive our approach to safety is. We embrace the opportunity to engage in dialogue so we can build more trust in sound science,” said Condon.
The company said it was providing access to 107 Bayer-owned glyphosate safety study reports that were submitted to the European Food Safety Authority as part of the substance authorization process in the European Union. The studies are accessible on Bayer’s transparency platform.
The news from Bayer comes ahead of an April 26 shareholders meeting in which some investors are calling for the head of Bayer CEO Werner Baumann for leading the company into the Monsanto acquisition. Monsanto’s top management walked away with millions of dollars in exit packages just before the first Roundup cancer trial, leaving Bayer holding the bag for the litigation losses and the bad publicity. Since last summer, the company has seen an exodus of customers as retailers, cities, school districts and others say they are backing away from the Monsanto herbicides.
As Bayer focuses on its messaging outside the court room, epidemiologist Beate Ritz, professor at the University of California Los Angeles School of Public Health, is due to take the stand today in Pilliod v. Monsanto, the third Roundup cancer trial. Ritz has testified in the two prior trials that her analysis of several scientific studies shows that there is a “credible link” between glyphosate-based herbicides such as Monsanto’s Roundup and non-Hodgkin’s lymphoma.
The current case was brought by Alva and Alberta Pilliod, a married couple who both have non-Hodgkin lymphoma they allege is due to years of Roundup use.
Following Ritz will be testimony from Dennis Weisenburger, a pathologist specializing in studying the causes of non-Hodgkin lymphoma. Weisenburger testified in the Edwin Hardeman v. Monsanto trial that Roundup is a “substantial cause” of cancer in people who are exposed.
Meanwhile, plaintiffs’ attorneys continue to worry about what they believe to be “geofencing” by Monsanto. Geofencing is a popular advertising technique that delivers specific messaging/content to anyone within a specific geographic area designated by the company or group paying for the ad. The area can be very small, a mile radius around a specific address, for instance. Anyone within that designated area using an app on a smart phone – such as a weather app or a game – would then be delivered the ad. Targeted individuals don’t have to be searching for information; it just appears on their smart phone.
Plaintiffs’ attorneys raised the issue in the Hardeman case, and had concerns that Monsanto was pushing messaging to jurors through geofencing in the first Roundup cancer trial, which was brought by groundskeeper Dewayne “Lee” Johnson.
In the Pilliod case, the issue was discussed Thursday in court as the plaintiffs attorneys sought a judicial order to prohibit Monsanto from the tactic, but the judge was skeptical and declined to issue such an order.
PLAINTIFFS’ ATTORNEY BRENT WISNER: Your Honor, I think there’s one — and I get your point. I think just to clarify one procedural factual thing. Right? If I were to walk over to a juror personally and say to you, “Hey, Juror Number 3, Monsanto’s stuff causes cancer and all these studies show it,” I mean, that would be a mistrial. Instantaneously. That’s jury tampering. Right? Now if they do that same thing — if I did the same thing by targeting every person’s phone in this courtroom or every single person’s phone in this courthouse and pushing that information, that same message to them on their phone — and what happens is - I don’t know if you use your phone for this kind of purposes, but, for example, when I look at my ESPN app and I’m looking at the scores for the UCLA water polo team, or whatever, you know, there’s little ads that pop up.
THE COURT: Sure.
MR. WISNER: And those ads are saying “Federal judge says Roundup is safe.” That’s the kind of stuff
we’re seeing. We saw this happening with quite intensity in the Johnson trial. Numerous jurors during voir dire mentioned that they were having these things pushed on them as soon as they walked in the building. And so whether or not Monsanto is or is not doing that, I think that if they are, that should be
prohibited. That’s not really a point of First Amendment. That is now clearly targeting people that
they know they can’t speak to.
THE COURT: And you’re asking me to assign a subjective intent that I don’t know exists and it’s
still prior restraint. I mean, technology has taken us places probably we never thought it would go… I guess if I were picking sides, I might believe that. But I can’t pick sides.
The chickens are coming home to roost, as they say in farm country.
For the second time in less than eight months a US jury has found that decades of scientific evidence demonstrates a clear cancer connection to Monsanto’s line of top-selling Roundup herbicides, which are used widely by consumers and farmers. Twice now jurors have additionally determined that the company’s own internal records show Monsanto has intentionally manipulated the public record to hide the cancer risks. Both juries found punitive damages were warranted because the company’s cover-up of cancer risks was so egregious.
The juries saw evidence that Monsanto has ghost-written scientific papers, tried to silence scientists, scuttled independent government testing and cozied up to regulators for favorable safety reviews of glyphosate, the active ingredient in Roundup.
Even the US district judge Vince Chhabria, who oversaw the San Francisco trial that concluded Wednesday with an $80.2m damage award, had harsh words for Monsanto. Chhabria said there were “large swaths of evidence” showing that the company’s herbicides could cause cancer. He also said there was “a great deal of evidence that Monsanto has not taken a responsible, objective approach to the safety of its product … and does not particularly care whether its product is in fact giving people cancer, focusing instead on manipulating public opinion and undermining anyone who raises genuine and legitimate concerns about the issue.”
Monsanto’s new owner, the German pharmaceutical company Bayer, asserts that the juries and judges are wrong; the evidence of a cancer risk is invalid; the evidence of bad corporate conduct is misunderstood and out of context; and that the company will ultimately prevail.
Meanwhile, Monsanto critics are celebrating the wins and counting on more as a third trial got underway this week and 11,000 additional plaintiffs await their turn. As well, a growing number of communities and businesses are backing away from use of Monsanto’s herbicides. And investors are punishing Bayer, pushing share prices to a seven-year low on Thursday.
Susquehanna Financial Group analyst Tom Claps has warned shareholders to brace for a global settlement of between $2.5bn and $4.5bn.
“We don’t believe [Monsanto] will lose every single trial, but we do believe that they could lose a significant majority,” he told the Guardian.
Following the recent courtroom victories, some have cheered the notion that Monsanto is finally being made to pay for alleged wrongdoing. But by selling to Bayer last summer for $63bn just before the Roundup cancer lawsuits started going to trial, Monsanto executives were able to walk away from the legal mess with riches. The Monsanto chairman Hugh Grant’s exit package allowed him to pocket $32m, for instance.
Amid the uproar of the courtroom scuffles, a larger issue looms: Monsanto’s push to make use of glyphosate herbicides so pervasive that traces are commonly found in our food and even our bodily fluids, is just one example of how several corporate giants are creating lasting human health and environmental woes around the world. Monsanto and its brethren have targeted farmers in particular as a critical market for their herbicides, fungicides and insecticides, and now many farmers around the world believe they cannot farm without them.
Studies show that along with promoting illness and disease in people, these pesticides pushed by Bayer and Monsanto, DowDuPont and other corporate players, are endangering wildlife, soil health, water quality and the long-term sustainability of food production. Yet regulators have allowed these corporations to combine forces, making them ever more powerful and more able to direct public policies that favor their interests.
The Massachusetts senator Elizabeth Warren this week called for taking back some of that power. She announced on Wednesday a plan to break up big agribusinesses and work against the type of corporate capture of Washington we have seen in recent years.
It’s a solid step in the right direction. But it cannot undo the suffering of cancer victims, nor easily transform a deeply contaminated landscape to create a healthier future and unleash us from the chains of a pesticide-dependent agricultural system.
And while Bayer may dole out a few billion dollars in damages, who is really being made to pay?
We all are.
Newsweek Gets Ad Money from Bayer, Prints Op-Eds That Help Bayer
Newsweek failed to disclose the chemical industry connections of two opinion writers who argued today in an op-ed that glyphosate can’t be regulated. The commentary by Henry I. Miller and Stuart Smyth, both of whom have ties to Monsanto that were not disclosed in the piece, appeared soon after a federal jury handed cancer victim Edwin Hardeman an $80 million verdict against Monsanto (now Bayer), and said the company’s glyphosate-based Roundup herbicide was a “substantial factor” in causing Hardeman’s cancer.
Last year, we complained to Newsweek’s opinion editor about an op-ed Dr. Miller wrote attacking the organic industry that was based on pesticide industry sources and didn’t disclose Miller’s Monsanto ties. See our bizarre email exchange with the editor, Nicholas Wapshott, in which he declined to inform readers about the conflicts of interest. Wapshott is no longer at Newsweek, but Miller’s organic food attack still appears there, and today it was surrounded by Bayer advertisements promoting glyphosate.
Bayer ads surrounding Dr. Miller’s 2018 attack on organic food – March 28, 2019
Today’s op-ed in Newsweek, in which Miller and Smyth defended Monsanto and Roundup, provided these bios: Stuart J. Smyth is a professor in the Department of Agricultural and Resource Economics and holds the Industry Funded Research Chair in Agri-Food Innovation at the University of Saskatchewan. Henry I. Miller, a physician and molecular biologist, is a Senior Fellow at the Pacific Research Institute. He was the founding director of the Office of Biotechnology at the U.S. Food & Drug Administration.
Here’s what Newsweek did not disclose to its readers about the authors:
Henry Miller’s Monsanto ties:
In 2017, the New York Times reported that Dr. Miller published an article in Forbes defending glyphosate that had been ghostwritten by Monsanto. Forbes severed ties with Miller and deleted all his articles.
Miller has a long history of partnering with – and pitching his PR services to – corporations that need help convincing the public their products aren’t dangerous and don’t need to be regulated.
Stuart Smyth’s Monsanto ties:
Dr. Smyth also collaborates with the agrichemical industry on PR projects, according to emails obtained by U.S. Right to Know and published in the UCSF Chemical Industry Documents Archive.
Emails from 2016 indicate that Dr. Smyth receives “program support” from Monsanto. The email from Monsanto Canada’s Public and Industry Affairs Director asks Dr. Smyth to send the “invoice for this year’s contribution.”
Newsweek has a duty to inform its readers about the chemical industry connections of writers and sources who argue in Newsweek for the safety and necessity of pesticides linked to cancer.
propaganda: information, especially of a biased or misleading nature, used to promote or publicize a particular political cause or point of view
Just four corporations now control three quarters of the global supply of seeds and pesticides. Public oversight of their activities is crucial for a safe and healthy food supply. Yet all of these companies – Monsanto/Bayer, DowDuPont, Syngenta/ChemChina and BASF – have documented histories of hiding the health risks and environmental impacts of their products. Since their records do not inspire trust, they often make use of third-party allies who promote the industry’s commercial and political agenda to the public, media, regulators and policy makers, while appearing to be acting independently of industry.
The public has a right to know about groups and people who collaborate with agrichemical corporations to push industry messaging and policy agendas. U.S. Right to Know has uncovered many documents that reveal, for the first time, how companies are working behind the scenes with academics, journalists and independent-sounding groups, in ways that are not disclosed to the public, to promote genetically engineered foods and pesticides and stave off regulations. The evidence is described in our fact sheets about key players in the agrichemical industry propaganda network:
Study says evidence ‘supports link’ between exposure to glyphosate and increased risk
This article was originally published in the Guardian.
By Carey Gillam
A broad new scientific analysis of the cancer-causing potential of glyphosate herbicides, the most widely used weedkilling products in the world, has found that people with high exposures to the popular pesticides have a 41% increased risk of developing a type of cancer called non-Hodgkin lymphoma.
The evidence “supports a compelling link” between exposures to glyphosate-based herbicides and increased risk for non-Hodgkin lymphoma (NHL), the authors concluded, though they said the specific numerical risk estimates should be interpreted with caution.
The findings by five US scientists contradict the US Environmental Protection Agency’s (EPA) assurances of safety over the weed killer and come as regulators in several countries consider limiting the use of glyphosate-based products in farming.
Monsanto and its German owner Bayer AG face more than 9,000 lawsuits in the US brought by people suffering from NHL who blame Monsanto’s glyphosate-based herbicides for their diseases. The first plaintiff to go to trial won a unanimous jury verdict against Monsanto in August, a verdict the company is appealing. The next trial, involving a separate plaintiff, is set to begin on 25 February, and several more trials are set for this year and into 2020.
Monsanto maintains there is no legitimate scientific research showing a definitive association between glyphosate and NHL or any type of cancer. Company officials say the EPA’s finding that glyphosate is “not likely” to cause cancer is backed by hundreds of studies finding no such connection.
The company claims the scientists with the International Agency for Research on Cancer (IARC) who classified glyphosate as a probable human carcinogen in 2015 engaged in improper conduct and failed to give adequate weight to several important studies.
But the new analysis could potentially complicate Monsanto’s defense of its top-selling herbicide. Three of the study authors were tapped by the EPA as board members for a 2016 scientific advisory panel on glyphosate. The new paper was published by the journal Mutation Research /Reviews in Mutation Research, whose editor in chief is EPA scientist David DeMarini.
The study’s authors say their meta-analysis is distinctive from previous assessments. “This paper makes a stronger case than previous meta-analyses that there is evidence of an increased risk of NHL due to glyphosate exposure,” said co-author Lianne Sheppard, a professor in the Environmental and Occupational Health Sciences department at the University of Washington. “From a population health point of view there are some real concerns.”
Sheppard was one of the scientific advisers to the EPA on glyphosate and was among a group of those advisers who told the EPA that it failed to follow proper scientific protocols in determining that glyphosate was not likely to cause cancer. “It was wrong,” Sheppard said of the EPA glyphosate assessment. “It was pretty obvious they didn’t follow their own rules. “Is there evidence that it is carcinogenic? The answer is yes.”
An EPA spokesperson said: “We are reviewing the study.” Bayer, which bought Monsanto in the summer of 2018, did not respond to a request for comment about the study.
A Bayer statement on glyphosate cites the EPA assessment and says that glyphosate herbicides have been “extensively evaluated” and are proven to be a “safe and efficient weed control tool”.
The study authors said their new meta-analysis evaluated all published human studies, including a 2018 updated government-funded study known as the Agricultural Health Study (AHS). Monsanto has cited the updated AHS study as proving that there is no tie between glyphosate and NHL. In conducting the new meta-analysis, the researchers said they focused on the highest exposed group in each study because those individuals would be most likely to have an elevated risk if in fact glyphosate herbicides cause NHL.
Looking only at individuals with real-world high exposures to the pesticide makes it is less likely that confounding factors may skew results, the authors said. In essence – if there is no true connection between the chemical and cancer then even highly exposed individuals should not develop cancer at significant rates.
In addition to looking at the human studies, the researchers also looked at other types of glyphosate studies, including many conducted on animals.
“Together, all of the meta-analyses conducted to date, including our own, consistently report the same key finding: exposure to GBHs are associated with an increased risk of NHL,” the scientists concluded.
David Savitz, professor of epidemiology in the Brown University School of Public Health, said the work was “well conducted” but lacking “fundamentally new information”.
“I would suggest it sustains the concern and need for assessment but doesn’t put the question to rest in any definitive sense,” Savitz said.
In a statement Bayer later said, “[The study] does not provide new epidemiology data; instead, it is a statistical manipulation that is at odds with the extensive body of science, 40 years of real world experience and the conclusions of regulators.”
It added: “[The study] provides no scientifically valid evidence that contradicts the conclusions of the extensive body of science demonstrating that glyphosate-based herbicides are not carcinogenic.”
Jay Byrne: Meet the Man Behind the Monsanto PR Machine
Monsanto’s former Director of Corporate Communications Jay Byrne, president of the public relations firm v-Fluence, is a key player in the covert propaganda and lobbying campaigns of the world’s largest agrichemical companies. Emails obtained by U.S. Right to Know, posted in the UCSF Chemical Industry Documents Archive, reveal a range of deceptive tactics Byrne and other industry allies are using to promote and defend GMO foods and pesticides.
The examples here showcase some of the ways companies are moving their messaging into the public arena from behind the cover of neutral-sounding front groups, government helpers and academics who appear to be independent as they work with corporations or their PR consultants.
Clients are top agrichemical, agribusiness and drug companies and tradegroups
Byrne’s client list has included a range of the largest agribusiness and pharmaceutical companies and business groups, including the American Chemistry Council, Syngenta, AstraZeneca, Monsanto, Pfizer, the International Rice Research Institute, the American Farm Bureau, National Corn Growers Association, Grocery Manufacturers Association, Rohm & Haas and the pesticide industry trade group CropLife.
Cooked up academic front group to attack Monsanto critics
A key strategy of the agrichemical industry, as the New York Times reported, is to deploy “white hat” professors to fight the industry’s PR and lobbying battles from behind the cover of the “gloss of impartiality and weight of authority that come with a professor’s pedigree.”
In March 2010, Byrne and University of Illinois Professor Bruce Chassy discussed setting up a front group called “Academics Review” that could attract donations from corporations while appearing to be independent. Byrne compared the idea to the Center for Consumer Freedom (a front group run by infamous corporate propaganda front-man Rick Berman), which “has cashed in on this to the extreme; and I think we have a much better concept.” Byrne described an “‘opportunities’ list with targets” they could go after. Byrne wrote to Dr. Chassy:
In November 2010, Byrne wrote to Chassy again, “It will be good to get the next phase of work on Academics Review going – we’ve got a relative slow first quarter coming up in 2011 if business remains the same.” Byrne offered to “schedule some pro bono search engine optimization time” for his team to counter a GMO critic’s online influence. Byrne concluded the email, “As always, would love to find the next topic (and sponsor) to broaden this while we are able.”
In 2014, Academics Review released a report attacking the organic industry as a marketing scam; in its own marketing materials for the report, Academics Review claimed to be independent and did not disclose its agrichemical industry funding.
“US government-GLP-Byrne projects” to sway journalists
Byrne’s lobbying and PR operations for the GMO and pesticide industry intersect at many points with the work of Jon Entine, another key figure in agrichemical industry defense campaigns. Entine directs the Genetic Literacy Project, which he launched in 2011 when Monsanto was a client of his PR firm. (Entine’s PR firm ESG MediaMetrics listed Monsanto as a client on its website in 2010, 2011, 2012 and up to January 2013, according to internet archives still available online.)
In December 2013, Entine wrote to Max T. Holtzman, who was then acting deputy undersecretary at the U.S. Department of Agriculture, to propose collaborating on a series of what he described as “US government-GLP-Byrne projects” to promote GMOs. Entine wrote to Holtzman:
Entine’s proposed “US government-GLP-Byrne” projects included a “Boot Camp and Response Swat Team” to prepare third-party academics for “potential legislative engagement on [GMO] labeling and related issues,” a “journalism conclave” to bolster media coverage about food security challenges and “provide coaching to younger journalists,” a global media outreach campaign to promote acceptance of biotechnology, and “multi-media content and placements from credible sources” reinforcing key themes “with segments and footage made available on U.S. government websites, GLP and other platforms.”
Holtzman responded, “Thanks Jon. It was great meeting you as well. I think your outline below provides natural intersection points where usda/USG messaging and your efforts intersect well. I’d like to engage further and loop other folks here at usda not only from the technical/trade areas but from our communications shop as well.”
Taxpayer-funded, Monsanto-aligned videos to promote GMOs
A series of taxpayer-funded videos produced in 2012 to promote genetically engineered foods provide another example of how academics and universities push corporate-aligned messaging. Byrne’s PR firm v-Fluence helped create the videos that were “designed to appear a little low budget and amateurish,” according to an email from University of Illinois Professor Bruce Chassy.
Sachs offered to assist with messaging of future videos by sharing the results of focus group tests Monsanto was conducting. Dr. Chassy invited Sachs to offer suggestions for future video topics and asked him to send along the Monsanto focus group results.
Training scientists and journalists to frame the debate about GMOs and pesticides
Byrne was on the organizing team, along with Cami Ryan (who now works for Monsanto) and Bruce Chassy (who was receiving funds from Monsanto that weren’t publicly disclosed), according to emails from Entine and Ryan.
Bonus Eventus: the agrichemical industry’s social media echo chamber
A key service Byrne provides to agrichemical promotional efforts is his “Bonus Eventus community” that supplies academics and other industry allies with talking points and promotional opportunities. Internal documents (page 9) describe Bonus Eventus as “a private social networking portal that serves as a communication cooperative for agriculture-minded scientists, policy makers and other stakeholders.” Members receive Byrne’s newsletter, plus access to his reference library of agribusiness topics, “stakeholder database” of influential people in the GMO debate, and trainings and support for social media engagement.
When a group of Nobel laureates called on Greenpeace to stop opposing genetically engineered rice, it looked like an independent effort. But behind the curtain of impressive credentials were the helping hands of two key players in the agrichemical industry’s PR lobby: Jay Byrne and a board member of the Genetic Literacy Project. Byrne was posted at the door at a National Press Club event promoting a group called Support Precision Agriculture. The .com version of that website redirects to the Genetic Literacy Project, a front group that works with Monsanto on PR projects without disclosing those ties.
Sir Richard Roberts, a biochemist who said he organized the Nobel laureate letter, explained the backstory in an FAQ on the website. Dr. Roberts said the “campaign has been pretty inexpensive so far,” consisting mostly of his salary paid by his employer New England Biolabs, and out-of-pocket expenses paid by Matt Winkler. Winkler, chairman of the Winkler Foundation, is a funder and board member of Genetic Literacy Project. Dr. Roberts explained that Winkler “enlisted a friend, Val Giddings,” (the former biotech trade group VP) who “suggested Jay Byrne,” who offered pro bono logistical support for the press event.
In his FAQ, Dr. Roberts dismissed Dr. Stone’s research as “not an accurate representation of the state of affairs,” and instead pointed to industry-connected sources who will be familiar to readers of Byrne’s Bonus Eventus newsletter: Julie Kelly, Henry Miller and Academics Review.
The press event took place at a critical moment for industry, and generated a helpful story in the Washington Post, a week before Congress voted to prohibit states from labeling GMOs.
Reporting for The Guardian in 2002, George Monbiot described a covert tactic that agrichemical corporations and their PR operatives have been using for decades to promote and defend their products: creating fake personalities and fake websites to silence critics and influence online search results.
Monbiot reported that “fake citizens” (people who did not actually exist) “had been bombarding internet listservers with messages denouncing the scientists and environmentalists who were critical of GM crops” – and the fake citizens had been traced back to Monsanto’s PR firm Bivings.
Monbiot described Jay Byrne’s connection to Bivings:
“think of the internet as a weapon on the table … somebody is going to get killed.”
“At the end of last year, Jay Byrne, formerly [Monsanto’s] director of internet outreach, explained to a number of other firms the tactics he had used at Monsanto. He showed how, before he got to work, the top GM sites listed by an internet search engine were all critical of the technology. Following his intervention, the top sites were all supportive ones (four of them established by Monsanto’s PR firm Bivings). He told them to ‘think of the internet as a weapon on the table. Either you pick it up or your competitor does, but somebody is going to get killed.’ While he was working for Monsanto, Byrne told the internet newsletter Wow that he ‘spends his time and effort participating’ in web discussions about biotech. He singled out the site AgBioWorld, where he ‘ensures his company gets proper play’. AgBioWorld is the site on which [fake citizen] Smetacek launched her campaign.”
A 2013 Power Point presentation showcases the role Byrne plays for his clients in the agrichemical industry. Here he explains his theories about eco-advocates, ranks their influence online and urges companies to pool their resources to confront them, in order to avoid “regulatory and market constraints.”
Glyphosate, a synthetic herbicide patented in 1974 by the Monsanto Company and now manufactured and sold by many companies in hundreds of products, has been associated with cancer and other health concerns. Glyphosate is best known as the active ingredient in Roundup-branded herbicides, and the herbicide used with “Roundup Ready” genetically modified organisms (GMOs).
Herbicide tolerance is the most prevalent GMO trait engineered into food crops, with some 90% of corn and 94% of soybeans in the U.S. engineered to tolerate herbicides, according to USDA data. A 2017 study found that Americans’ exposure to glyphosate increased approximately 500 percent since Roundup Ready GMO crops were introduced in the U.S in 1996. Here are some key facts about glyphosate:
Americans have applied 1.8 million tons of glyphosate since its introduction in 1974.
Worldwide 9.4 million tons of the chemical has been sprayed on fields – enough to spray nearly half a pound of Roundup on every cultivated acre of land in the world.
Globally, glyphosate use has risen almost 15-fold since Roundup Ready GMO crops were introduced.
The scientific literature and regulatory conclusions regarding glyphosate and glyphosate-based herbicides show a mix of findings, making the safety of the herbicide a hotly debated subject:
In 2015, the World Health Organization’s International Agency for Research on Cancer (IARC) classified glyphosate as “probably carcinogenic to humans” after reviewing years of published and peer-reviewed scientific studies. The team of international scientists found there was a particular association between glyphosate and non-Hodgkin lymphoma.
At the time of the IARC classification, the Environmental Protection Agency (EPA) was conducting a registration review. The EPA’s Cancer Assessment Review Committee (CARC) issued a report in September 2016 concluding that glyphosate was “not likely to be carcinogenic to humans” at doses relevant to human health. In publishing the CARC report, the EPA said that it was beginning work with the National Toxicology Program to investigate the mechanisms and toxic effects of glyphosate formulations.
The agency then convened a Scientific Advisory Panel (SAP) in December 2016 to review the CARC report conclusion that glyphosate was not likely to be carcinogenic. The scientific advisory panel members were divided in their assessment of EPA’s work, with some finding the EPA erred in how it evaluated certain research. Additionally, the EPA’s Office of Research and Development determined that the agency’s Office of Pesticide Programs had not followed proper protocols in its evaluation of glyphosate. An ORD memo stated that the government scientists agreed in part with IARC and believed EPA was not properly following guidelines in coming to the conclusion that glyphosate was not likely to be carcinogenic. ORD said the evidence could be deemed to support a “likely” carcinogenic or “suggestive” evidence of carcinogenicity classification. Nevertheless the EPA issued a draft report on glyphosate in December 2017 continuing to hold that the chemical is not likely to be carcinogenic.
The WHO/FAO Joint Meeting on Pesticide Residues determined that glyphosate was unlikely to pose a carcinogenic risk to humans from exposure through the diet, though the finding was tarnished by conflict of interest concerns after it was revealed that certain members of the group, including its chair, worked for the International Life Sciences Institute, a group funded in part by Monsanto and one of its lobbying organizations.
On March 28, 2017, the California Environmental Protection Agency’s Office of Environmental Health Hazard Assessment confirmed that it would add glyphosate to California’s Proposition 65 list of chemicals known to cause cancer. Monsanto sued to block the action but the case was dismissed. In a separate case, the court found that California could not require cancer warnings for products containing glyphosate. On June 12, 2018, the United States District Court for the Eastern District of California denied the California Attorney General’s request for the court to reconsider the decision. The court found that California could only require commercial speech that disclosed “purely factual and uncontroversial information,” and the science surrounding glyphosate carcinogenicity was not proven.
A long-running U.S. government-backed prospective cohort study of farm families in Iowa and North Carolina has not found any connections between glyphosate use and non-Hodgkin lymphoma, though researchers found that “among applicators in the highest exposure quartile, there was an increased risk of acute myeloid leukemia (AML) compared with never users…” The most recent published update to the study was made public in late 2017.
New studies in 2019 report cancer links and concerns about the validity of the EPA classification:
A February 2019 meta-analysis of scientific studies reported a “compelling link” between glyphosate-based herbicides and non-Hodgkin lymphoma. Three of the study authors were members of the EPA’s scientific advisory panel on glyphosate who have stated publicly that the EPA failed to follow proper scientific practices in its glyphosate assessment.
A March 2019 study analyzed data from more than 30,000 farmers and agricultural workers from studies done in France, Norway and the U.S., and reported links between glyphosate and diffuse large B-cell lymphoma.
More than 650 lawsuits against Monsanto Co. are part of multi district litigation (MDL) being overseen by Judge Vince Chhabria in U.S. District Court in San Francisco, filed by people alleging that exposure to Roundup herbicide caused them or their loved ones to develop non-Hodgkin lymphoma, and that Monsanto covered up the risks. An estimated 9,000 similar actions are pending in state courts. U.S. Right to Know is posting key documents from the litigation on our Monsanto Papers pages. See Carey Gillam’s Roundup Trial Tracker for news and tips about the ongoing legislation.
A study for the European Parliament published January 15, 2019 asserts that the EU approval of glyphosate was based on plagiarized text from Monsanto. The study found plagiarism in 50.1 percent of chapters dealing with the assessment of published studies on health risks related to glyphosate in Germany’s Federal Institute for Risk Assessment, including whole paragraphs and entire pages of plagiarized text.
See also 2018 journal articles about scientific interference:
The first trial concluded in August 2018 with the jury ruling that Monsanto’s weed killer was a substantial contributing factor in causing DeWayne “Lee” Johnson’s cancer, and ordering Monsanto to pay $289.25 million in damages, including $250 million in punitive damages. The judge in the case reduced the punitive damages to $39 million, bringing the total award to $78 million. Monsanto declared it would appeal and Johnson has cross-appealed, seeking to reinstate the jury award.
March 19, 2019 update: In a blow to Bayer, a federal journey handed a first-round victory to plaintiff Edwin Hardeman, as the six jury members found that Hardeman’s exposure to Roundup was a “substantial factor” in causing his non-Hodgkin lymphoma. The jury decision means the trial now moves into a second phase in which jurors will take up the issue of liability and damages.
Recent studies have shown adverse biological effects from low-dose exposures to glyphosate at levels to which people are routinely exposed.
A birth cohort study in Indiana published in 2017 – the first study of glyphosate exposure in US pregnant women using urine specimens as a direct measure of exposure – found detectable levels of glyphosate in more than 90% of the pregnant women tested and found the levels were significantly correlated with shortened pregnancy lengths.
A 2018 ecological and population study conducted in Argentina found high concentrations of glyphosate in the soil and dust in agricultural areas that also reported higher rates of spontaneous abortion and congenital abnormalities in children, suggesting a link between environmental exposure to glyphosate and reproductive problems. No other relevant sources of pollution were identified.
A 2017 study associated chronic, very low-level glyphosate exposures to non-alcoholic fatty liver disease in rats. According to the researchers, the results “imply that chronic consumption of extremely low levels of a GBH formulation (Roundup), at admissible glyphosate-equivalent concentrations, are associated with marked alterations of the liver proteome and metabolome,” the biomarkers for NAFLD.
A 2018 rat study conducted by the Ramazzini Institute reported that low-dose exposures to Roundup at levels considered safe significantly altered the gut microbiota in some of the rat pups. Another 2018 study reported that higher levels of glyphosate administered to mice disrupted the gut microbiota and caused anxiety and depression-like behaviors.
Some farmers use glyphosate on non-GMO crops such as wheat, barley, oats, and lentils to dry down the crop ahead of harvest in order to accelerate the harvest. This practice, known as desiccation, may be a significant source of dietary exposure to glyphosate.
Glyphosate Found in Food: U.S. Drags Its Feet on Testing
The USDA quietly dropped a plan to start testing food for residues of glyphosate in 2017. Internal agency documents obtained by U.S. Right to Know show the agency had planned to start testing over 300 samples of corn syrup for glyphosate in April 2017. But the agency killed the project before it started. The U.S. Food and Drug Administration began a limited testing program in 2016, but the effort was fraught with controversy and internal difficulties and the program was suspended in September 2016. Both agencies have programs that annually test foods for pesticide residues but both have routinely skipped testing for glyphosate.
Before the suspension, one FDA chemist found alarming levels of glyphosate in many samples of U.S. honey, levels that were technically illegal because there have been no allowable levels established for honey by the EPA. Here is a recap of news about glyphosate found in food:
October 2018: FDA issued its first-ever report showing the results of its glyphosate residue in food testing. The FDA said no residues of glyphosate were found in milk or eggs, but residues were found in 63.1 percent of corn samples and 67 percent of soybean samples, according to FDA data. The agency did not disclose in that report the findings of glyphosate in oatmeal or honey products.